Cargando…
Construction of possible integrated predictive index based on EGFR and ANXA3 polymorphisms for chemotherapy response in fluoropyrimidine-treated Japanese gastric cancer patients using a bioinformatic method
BACKGROUND: Variability in drug response between individual patients is a serious concern in medicine. To identify single-nucleotide polymorphisms (SNPs) related to drug response variability, many genome-wide association studies have been conducted. METHODS: We previously applied a knowledge-based b...
Autores principales: | Takahashi, Hiro, Kaniwa, Nahoko, Saito, Yoshiro, Sai, Kimie, Hamaguchi, Tetsuya, Shirao, Kuniaki, Shimada, Yasuhiro, Matsumura, Yasuhiro, Ohtsu, Atsushi, Yoshino, Takayuki, Doi, Toshihiko, Takahashi, Anna, Odaka, Yoko, Okuyama, Misuzu, Sawada, Jun-ichi, Sakamoto, Hiromi, Yoshida, Teruhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609065/ https://www.ncbi.nlm.nih.gov/pubmed/26475168 http://dx.doi.org/10.1186/s12885-015-1721-z |
Ejemplares similares
-
Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect
por: Takahashi, Hiro, et al.
Publicado: (2014) -
Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003) -
Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
por: Yoshino, Takayuki, et al.
Publicado: (2018) -
NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis
por: Doi, Toshihiko, et al.
Publicado: (2017) -
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial
por: Kuboki, Yasutoshi, et al.
Publicado: (2023)